

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3279416

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
OLIVER BLEY	02/26/2015
PETRA LOOS	02/26/2015
BERND BIDLINGMAIER	03/05/2015
WALTER KAMM	02/26/2015
HARALD BERCHTOLD	03/02/2015
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	SANOFI
<b>Street Address:</b>	54, RUE LA BOETIE
<b>Internal Address:</b>	75008
<b>City:</b>	PARIS
<b>State/Country:</b>	FRANCE
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	14592750
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(857)300-4001
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	857-300-4004
<b>Email:</b>	bostonpatent@lathropgage.com, spageau@lathropgage.com
<b>Correspondent Name:</b>	JAMES H. VELEMA, ESQ.
<b>Address Line 1:</b>	LATHROP & GAGE LLPL
<b>Address Line 2:</b>	28 STATE STREET, 7TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02109
<b>ATTORNEY DOCKET NUMBER:</b>	564136: SA9-142
<b>NAME OF SUBMITTER:</b>	JAMES H. VELEMA, ESQ.
<b>SIGNATURE:</b>	/James H. Velema/
<b>DATE SIGNED:</b>	03/24/2015
<b>Total Attachments: 2</b>	

source=564136\_Assignment#page1.tif

source=564136\_Assignment#page2.tif

ASSIGNMENT AND AGREEMENT

Effective as of January 09, 2014, for value received and intending to be legally bound, I/we, the undersigned joint inventor(s) (Assignor(s)), sell, assign and transfer to Sanofi (Assignee), 54, rue La Boétie, 75008 Paris, France and its successors, assigns and legal representatives, the entire right, title and interest in and to my/our invention and any improvements thereon for all countries of the world, relating in and to the application for United States Letters Patent therefore, assigned Attorney Docket No. DE2014/005, entitled

Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives.

And for all patent applications which claim priority to or are derived from said priority applications:

European Patent (EP):	EP Application Filing Date:	January 9, 2014
	EP Application Filing No.:	14305024.3
USA (US):	US Application Filing Date:	January 9, 2014
	US Application Filing No.:	61/925484

and all the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said application(s), and under any and all Letters Patent which may be granted therefore, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including continuations, divisions, renewals, revivals, and any substitute applications of said United States application, and any and all patents which may issue thereon, and any reissues, pipelines and extensions, and governmental exclusivity rights of the same.

I/we state that I/we am/are an original inventor(s) of the claimed invention and authorize the filing of a patent application for the claimed invention.

I/we authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

I/we agree that, when requested, I/we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, and do all acts which may be necessary, desirable or convenient for securing and maintaining patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

I/we covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have full right to convey the same as herein expressed.

Signed at Frankfurt, Germany on this 26th day of February, 2015  
(City and Nation)

Signature: [Signature]  
Inventor's Name: Oliver Sley  
Residential Address: c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany

Witnessed by: Dirk Hörter [Signature]

Signed at Frankfurt, Germany on this 26<sup>th</sup> day of February, 2015  
(City and Nation)

Signature:   
Inventor's Name: **Petra Loos**  
Residential Address: **c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany**

Witnessed by:  



Signed at Frankfurt, Germany on this 5<sup>th</sup> day of March, 2015  
(City and Nation)

Signature:   
Inventor's Name: **Bernd Bidingmaier**  
Residential Address: **c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany**


Witnessed by:  

Signed at Frankfurt, Germany on this 26<sup>th</sup> day of February, 2015  
(City and Nation)

Signature:   
Inventor's Name: **Walter Kamm**  
Residential Address: **c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany**

Witnessed by:  

Signed at Frankfurt, Germany on this 2nd day of March, 2015  
(City and Nation)

Signature:   
Inventor's Name: **Harald Berchiold**  
Residential Address: **c/o Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am Main, Germany**

Witnessed by: 